The Vancouver-based company is currently advancing unique medicines and devices to treat mild traumatic brain injury and post-traumatic stress disorder, as well as other indications. With five provisional patents, a pre-clinical study underway and a drug delivery device in engineering development, Lobe is quickly making a name for itself in the world of psychedelics.
Lobe Sciences Ltd presents at Proactive's One2One virtual investor forum
Quick facts: Lobe Sciences Ltd
Price: 0.155 CAD
Market Cap: $25.62 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Lobe Sciences Ltd named herein, including the promotion by the Company of Lobe Sciences Ltd in any Content on the Site, the Company receives...FOR OUR FULL DISCLAIMER CLICK HERE